Piper Sandler Bullish on Xeris Pharmaceuticals (XERS) Following Physician Survey
Tweet Send to a Friend
Piper Sandler analyst David Amsellem reiterated an Overweight rating and $11.00 price target on Xeris Pharmaceuticals (NASDAQ: XERS) on favorable ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
